Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Delimpasi S, Dimopoulos MA, Straub J, Symeonidis A, Pour L, Hájek R, Touzeau C, Bhanderi VK, Berdeja JG, Pavlíček P, Matous JV, Robak PJ, Suryanarayan K, Miller A, Villarreal M, Cherepanov D, Srimani JK, Yao H, Labotka R, Orlowski RZ. Delimpasi S, et al. Among authors: cherepanov d. Am J Hematol. 2024 Sep;99(9):1746-1756. doi: 10.1002/ajh.27382. Epub 2024 Jun 10. Am J Hematol. 2024. PMID: 38856176 Clinical Trial.
Global epidemiology of amyloid light-chain amyloidosis.
Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Kumar N, et al. Among authors: cherepanov d. Orphanet J Rare Dis. 2022 Jul 19;17(1):278. doi: 10.1186/s13023-022-02414-6. Orphanet J Rare Dis. 2022. PMID: 35854312 Free PMC article.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Davies F, et al. Among authors: cherepanov d. Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10. Ann Hematol. 2021. PMID: 33970288 Free PMC article.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E. Sanchorawala V, et al. Among authors: cherepanov d. Am J Hematol. 2023 May;98(5):720-729. doi: 10.1002/ajh.26866. Epub 2023 Feb 14. Am J Hematol. 2023. PMID: 36708469 Free article. Clinical Trial.
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Bringhen S, Pour L, Benjamin R, Grosicki S, Min CK, C de Farias DL, Vorog A, Labotka RJ, Wang B, Cherepanov D, Cain LE, Manne S, Rajkumar SV, Dimopoulos MA. Bringhen S, et al. Among authors: cherepanov d. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):491-504. doi: 10.1016/j.clml.2023.03.007. Epub 2023 Mar 29. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37149398 Free article. Clinical Trial.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Lee HC, et al. Among authors: cherepanov d. Eur J Haematol. 2024 Aug;113(2):190-200. doi: 10.1111/ejh.14214. Epub 2024 Apr 23. Eur J Haematol. 2024. PMID: 38654611
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States.
Ailawadhi S, Cheng M, DerSarkissian M, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Cherepanov D. Ailawadhi S, et al. Among authors: cherepanov d. J Manag Care Spec Pharm. 2024 Dec;30(12):1431-1441. doi: 10.18553/jmcp.2024.24085. Epub 2024 Sep 9. J Manag Care Spec Pharm. 2024. PMID: 39612251 Free PMC article.
151 results